The Therapeutic Index (TI) is an important parameter in assessing the safety of drugs. It is used to measure the relationship between the safety and effectiveness of a drug.
OncoC4 Reveals FDA Approval for Investigational New Drug Application of Its Unique SIGLEC 10 Immune Checkpoint Blocker, ONC-841, Targeting Solid Tumors.
hC Bioscience Reveals Primary Project in Hemophilia and Shares Encouraging Early Results from Innovative Protein Modification Strategy Using Engineered tRNA Anticodons.
Hanmi Pharmaceutical will start a phase 1 clinical trial to evaluate the safety and effectiveness of its cancer immunotherapy, ‘BH3120’, in combination with MSD's KEYTRUDA® (pembrolizumab).
GPCRs, as key signal transduction molecules on the cell surface, regulate various physiological processes and constitute one-third of the targets for clinical drug applications.
Voydeya has been sanctioned in the EU as a supplementary treatment alongside ravulizumab or eculizumab for adults with PNH who still suffer from persistent haemolytic anaemia.